- A review in Science suggests glucagon-like peptide-1 (GLP-1) medications may be linked to better brain health.
- It’s still unclear whether they act directly on the brain or whether benefits stem from improved cardiometabolic health.
- Observational studies suggest GLP-1 medications may be associated with a lower risk of cognitive impairment and dementia in people with obesity or type 2 diabetes. However, a direct causal relationship hasn’t been proven.
- Semaglutide didn’t slow progression in two phase 3 trials of early Alzheimer’s disease.
GLP-1 medications have transformed obesity and type 2 diabetes treatment. Now, researchers are investigating whether the effects of this blockbuster class of drugs extend beyond weight loss and affect brain health.
A comprehensive new review published on November 5 in the journal Science evaluated the current evidence on how GLP-1 medications like semaglutide and tirzepatide may affect the brain across aging, cardiometabolic disease, and Alzheimer’s disease.
The authors of the review suggested that GLP-1 medications like Ozempic and Zepbound may offer brain health benefits. However, they were also left with the question of whether the medications act directly on the brain or whether better brain health is actually a consequence of improved cardiometabolic health.
Sheena Aurora, MD, vice president, Medical Affairs, Alzheimer’s Association, who wasn’t involved in the review, told Healthline that more research is needed to better understand the effects of GLP-1 drugs on the brain.
“While research suggests GLP-1s could reduce brain inflammation, improve blood vessel health, and even protect neurons, much broader, randomized clinical trials on GLP-1s and brain health, including in people with Alzheimer’s disease and other dementias, are needed,” she said.
GLP-1 medications like semaglutide, the active ingredient in Ozempic and Wegovy, mimic the GLP-1 hormone. Tirzepatide, the active ingredient in Mounjaro and Zepbound, also targets a second hormone pathway called GIP.
These medications have been shown to produce significant weight loss and improvements in cardiometabolic health.
This is important for brain health because obesity, type 2 diabetes, and vascular dysfunction are all linked with cognitive impairment and dementia. Insulin resistance and chronic inflammation may also link metabolic and brain health.
Analyses of large outcome trials and observational cohorts have suggested that GLP-1 medications may be associated with a reduced risk of cognitive impairment and dementia. However,
Around 200 preclinical and mechanistic studies have shown benefits for learning, memory, synaptic plasticity, and neuronal resilience, though results are heterogeneous in design and direction, so a clear consensus on magnitude and mechanism remains lacking.
It is also unclear how well GLP-1 medications reach the brain. They appear to reach certain areas, such as the hypothalamus, brainstem, and circumventricular organs, more readily than regions protected by the blood-brain barrier.
The report authors noted that some studies have shown that GLP-1 receptor agonists may reduce the risk of cognitive impairment and dementia in people with type 2 diabetes. This may be due to cognitive issues being linked to factors such as blood sugar, blood pressure, vascular health, and sleep.
Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who wasn’t involved in the report, told Healthline, “These findings are interesting, but like many of the other benefits associated with GLP-1 medications, a direct causal relationship has not yet been proven.”
“Rather, the benefits appear to be more closely tied to the reduction in obesity and better control of diabetes,” he said.
Aurora noted that growing evidence supports the heart-brain connection.
The research showed that the structured lifestyle intervention program also improved heart health risk factors, such as:
“U.S. POINTER can change those risk factors within 24 months, and better heart health risk-factor control was linked with better cognition,” Aurora said. “We’re also interested to see whether adding a drug like a GLP-1 to a U.S. POINTER-style lifestyle program improves cognition in at-risk older adults more than the program alone.”
To find out, the Alzheimer’s Association is funding the Prevention of Risk for Cognitive Decline through Combined Therapy (PROTECT-Cog) global phase 3 clinical trial.
PROTECT-Cog is a first-of-its-kind trial designed to evaluate whether combining a proven multidomain lifestyle intervention with a metabolism-targeting drug, like a GLP-1, can further reduce the risk of cognitive decline, mild cognitive impairment, and dementia in at-risk older adults.
Dung Trinh, MD, internist at MemorialCare Medical Group and Chief Medical Officer of Healthy Brain Clinic in Irvine, CA, who also wasn’t involved in the review, told Healthline, “I often remind my patients that what’s good for the heart is generally good for the brain.”
“The brain depends on a healthy cardiovascular system to deliver a constant supply of oxygen, glucose, and other nutrients. Conditions such as high blood pressure, diabetes, obesity, and high cholesterol can damage blood vessels, promote chronic inflammation, and increase the risk of stroke and vascular cognitive impairment,” he said.
“Over time, these changes can also contribute to the development or progression of dementia.”
Trinh added that while GLP-1 medications can improve several cardiometabolic risk factors, these improvements do not automatically translate into proven dementia prevention.
“Regular physical activity, a heart-healthy diet, adequate sleep, and management of cardiovascular risk factors remain essential strategies for maintaining brain health as we age,” he said.
When the report authors turned their attention to more stringent tests on semaglutide in people already living with early Alzheimer’s disease, the picture began to change.
Novo Nordisk’s
The studies showed that while semaglutide produced changes in several disease-related biomarkers, it didn’t slow the progression of Alzheimer’s disease.
This emphasizes that fixing metabolic issues might prevent cognitive decline in someone with obesity or diabetes. But it might not be enough to reverse the damage in someone with established Alzheimer’s disease, where profound synaptic loss and protein pathology have already occurred.
The review authors suggest that future research on obesity and diabetes should also include rigorous and specific cognitive testing.

Leave a Reply